YOLFTbeta
Scandinavian ChemoTech AB Series B

Scandinavian ChemoTech AB Series B

CMOTEC-B · ST · Healthcare / Biotechnology

2.65SEK-0.17 (-6.03%)

Price History

Full chart

Market Stats

Previous Close2.82
Open2.74
Day Range2.50 – 2.74
52-Week Range2.50 – 6.18
Volume53.95K
Market Cap96.21M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.24
Dividend Yield0.00%
Beta0.96
50-Day Avg3.62
200-Day Avg3.98

About

Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTech AB (publ) and changed its name to Neem's Hill AB in July 2026. The company was incorporated in 2013 and is headquartered in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Stefan Mohan Frick
  • Employees1
  • HeadquartersMedicon Village, Lund, Sweden, 223 63, Sweden
  • Websitehttps://chemotech.se

Leadership

  • Mr. Stefan Mohan FrickFounder, CEO, President & Director · b. 1974
  • Ann OhlssonHead of Finance · b. 1966

Financials

Income Statement

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--13.89K2.08M27.24K560.00K556.00K131.00K49.00K473.00K2.82M6.57M12.29M
Growth (%)---+14901.89%-98.69%+1955.57%-0.71%-76.44%-62.60%+865.31%+496.62%+132.67%+87.10%
Cost of Revenue-28.14K7.88K107.27K8.30M258.00K227.00K145.00K-274.00K528.00K1.17M1.79M16.78M
Gross Profit--28.14K6.01K1.98M-8.28M302.00K329.00K-14.00K323.00K-55.00K1.66M4.78M-4.50M
Gross Margin--43.28%94.85%-30383.52%53.93%59.17%-10.69%659.18%-11.63%58.72%72.75%-36.61%
Operating Expense-01.16M10.04M2.76K5.12M12.30M10.81M17.40M20.86M21.89M17.57M1.80M
Operating Income-7.46K-28.14K-1.15M-8.06M-8.28M-4.82M-11.97M-10.83M-17.08M-20.91M-20.24M-12.80M-6.30M
Operating Margin---8270.12%-386.70%-30393.64%-860.18%-2153.06%-8266.41%-34851.02%-4421.14%-717.12%-194.88%-51.30%
EBITDA--27.78K-1.15M-7.65M-7.72M-8.04M-11.92M-10.77M-17.03M-20.81M-19.58M-12.38M-4.33M
EBITDA Margin---8269.40%-366.90%-28341.81%-1435.18%-2143.53%-8223.66%-34746.94%-4399.15%-693.80%-188.49%-35.24%
Net Income-7.46K-28.14K-1.18M-8.14M-8.33M-4.80M-12.59M-11.66M-17.74M-22.75M-21.09M-13.72M-8.06M
Net Income Margin---8498.88%-390.48%-30582.56%-856.61%-2263.49%-8903.82%-36210.20%-4808.88%-747.38%-208.91%-65.58%
R&D--781.35K769.00K-3.85M4.10M1.28M2.77M2.91M2.57M1.90M-
R&D as % of Total Revenue--5623.62%36.89%-688.21%737.41%979.39%5661.22%614.59%91.11%28.94%-
Interest Expense-031.88K-076.00K358.00K835.00K675.00K1.90M1.40M1.18M1.95M
Interest Expense % of Total Revenue--229.48%-0.00%13.57%64.39%637.40%1377.55%401.06%49.72%17.94%15.84%

Balance Sheet

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets44.41K65.90K6.65M16.83M12.84M22.81M17.49M15.99M25.81M21.70M14.87M13.38M13.20M
Total Liabilities-19.63K5.78M2.24M2.56M2.31M7.76M6.75M1.89M7.71M3.84M7.40M10.01M
Total Equity44.41K46.27K868.64K14.58M10.29M20.50M9.73M9.24M23.92M13.99M11.03M5.98M3.19M
Cash44.41K12.20K3.32M11.47M4.63M6.76M2.86M1.49M8.68M5.85M923.00K949.00K3.67M
Total Debt--5.40M684.21K1.46M605.00K5.29M2.71M53.00K----
Net Debt-44.41K-12.20K-2.57M-10.79M-4.03M-6.32M2.43M1.23M-8.63M-5.85M-923.00K-949.00K-3.67M

Cash Flow

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--40.91K-474.99K-7.52M-14.97M-4.58M-11.23M-8.49M-19.18M-19.63M-18.23M-13.14M-3.75M
Investing Cash Flow--21.30K-3.03M-2.05M-5.27M-8.14M-4.32M-1.83M-3.33M-603.00K-468.00K-2.00K-426.00K
Financing Cash Flow-30.00K6.81M17.73M21.55M14.85M10.84M8.98M29.71M17.26M13.77M13.17M6.89M
Capital Expenditure021.30K3.01M96.00K4.27M4.13M4.32M1.83M3.18M331.00K680.00K46.00K437.00K
Free Cash Flow--62.20K-3.49M-7.61M-19.24M-8.71M-15.54M-10.32M-22.36M-19.96M-18.91M-13.19M-4.18M
Dividends Paid--0-302.63K--------
FCF to OCF-152.06%734.22%101.28%128.51%190.22%138.46%121.52%116.58%101.69%103.73%100.35%111.67%
Dividend Paid to FCF--0.00%--1.57%--------

Earnings

Report DateDec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Feb 27, 2019May 29, 2019Aug 28, 2019Nov 27, 2019Feb 26, 2020Jun 3, 2020Sep 2, 2020Dec 2, 2020Mar 3, 2021May 4, 2021Aug 17, 2021Nov 2, 2021Mar 8, 2022May 3, 2022Aug 16, 2022Nov 22, 2022Mar 7, 2023May 25, 2023Aug 15, 2023Oct 17, 2023Mar 5, 2024May 7, 2024Aug 13, 2024Nov 5, 2024Mar 4, 2025May 6, 2025Aug 13, 2025Nov 5, 2025Mar 4, 2026May 29, 2026
EPS Estimate------------------------------------
EPS Actual-1.63-1.17-1.25-1.12-0.94-0.62-0.28-0.68-0.49-0.64-1.04-0.77-0.42-0.45-0.44-0.33-0.44-0.65-0.56-0.49-0.62-0.58-0.59-0.42-0.48-0.33-0.35-0.18-0.18-0.14-0.14-0.14-0.04-0.05-0.10-0.06
Surprise------------------------------------
Timing---------------Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market----

Key Statistics & Ratios

Market Cap96.21M
Enterprise Value70.26M
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.63
Price / Book48.64
EPS-0.24
Book Value0.064
Revenue (TTM)12.61M
Gross Profit (TTM)11.03M
EBITDA-5.09M
Profit Margin-50.01%
Operating Margin-49.29%
Return on Equity-236.48%
Return on Assets-27.28%
Shares Outstanding23.80M
Shares Float13.07M
Beta0.96
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 30, 2024230:221
  • Apr 20, 20201061:839
  • May 21, 2018296:273